Press Release

Viking Therapeutics Announces $632.5 Million Public Offering of Common Stock

March 4, 2024

San Francisco – March 4, 2024 – Cooley advised the underwriters of Viking Therapeutics (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, on its $632.5 million public offering of common stock. Partners Denny Won, Kristin VanderPas, Charlie Kim and David Peinsipp led the Cooley team advising the underwriters.

Listed on Nasdaq as VKTX, Viking issued and sold 7,441,650 shares of common stock, priced at $85 per share, which includes the full exercise of the underwriters’ option to purchase 970,650 additional shares of Viking’s common stock. The offering closed on March 4, 2024.

Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel and Truist Securities acted as joint book-running managers for the offering, while Oppenheimer & Co. acted as lead manager. BTIG, HC Wainwright & Co., Maxim Group, and Laidlaw & Company (UK) Ltd. acted as co-managers for the offering.

About Cooley

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has over 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.